印度生物技术部门的价值为150B美元,要求增加私营部门研发投资, India's biotech sector, valued at $150B, calls for increased private-sector R&D investment and streamlined regulations for innovation leadership, per BIRAC official Dr. Jitendra Kumar.

印度生物技术部门的价值为1 500亿美元,但根据BIRAC的Jitendra Kumar博士的说法,这一部门的潜力尚未开发。 India's biotechnology sector is valued at $150 billion but has significant untapped potential, according to Dr. Jitendra Kumar of BIRAC. 自2012年以来,生物技术新建企业的数量从300家猛增到8 000多家。 Since 2012, the number of biotech startups has surged from 300 to over 8,000. 然而,印度仅将其国内生产总值的0.8%投资于研发,落后于美国和中国等国家。 However, India invests only 0.8% of its GDP in R&D, lagging behind countries like the US and China. 为加强创新并成为全球领导者,BIRAC强调需要增加私营部门的研发投资和简化规章。 To enhance innovation and become a global leader, BIRAC emphasizes the need for increased private-sector R&D investment and streamlined regulations.